Unlike general enterprise AI where a wrong answer is an inconvenience, errors in healthcare AI can be fatal. This high-stakes environment forces companies like Abridge to adopt extremely rigorous offline evaluation and phased, progressive rollouts, a far more cautious approach than typical "move fast" software development.

For new technologies to gain adoption in pharma, the central value proposition must be about de-risking decisions. Leaders and regulators often view the technology as a "black box" and are less concerned with its mechanics than with its ability to give them confidence in making safer, more reliable choices.

In aerospace and defense, the classic Silicon Valley motto is dangerous. Hardware failures can lead to physical harm and mission failure, unlike software bugs. This necessitates a rigorous testing and evaluation stack to prevent edge cases before deployment, making speed secondary to safety and reliability.

Moving technology from academia to a startup requires a crucial mindset shift. The academic goal of publishing data must be replaced by the industry requirement of extensive validation. For Vivtex, this single piece of advice added years of work but was essential for creating a commercially viable platform.

Rapid trial generation is counterproductive if accelerated drafts lack scientific rigor and regulatory precision. Teams adopting clinical AI must strike an optimal balance between reducing generation timelines and maintaining the strict quality required to pass regulatory scrutiny.

Kindbody's rapid, venture-backed expansion mirrored a tech startup's trajectory. However, this 'Silicon Valley style' disruption in a sensitive medical field like fertility care ultimately led to significant patient disillusionment, revealing a fundamental clash between a speed-focused business model and the requirements of trust-based medicine.

In high-stakes fields like medtech, the "fail fast" startup mantra is irresponsible. The goal should be to "learn fast" instead—maximizing learning cycles internally through research and simulation to de-risk products before they have real-world consequences for patient safety.

In high-stakes fields like healthcare, the cost of an AI error is immense. Product leaders must prioritize safety, reliability, and the reproducibility of outcomes. A complete audit trail is non-negotiable, as it enables the reversal of incorrect decisions and ensures accountability.

Dr. Jordan Schlain frames AI in healthcare as fundamentally different from typical tech development. The guiding principle must shift from Silicon Valley's "move fast and break things" to "move fast and not harm people." This is because healthcare is a "land of small errors and big consequences," requiring robust failure plans and accountability.